Acquired familial Mediterranean fever associated with a somatic MEFV mutation in a patient with JAK2 associated post-polycythemia myelofibrosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Acquired familial Mediterranean fever associated with a somatic MEFV mutation in a patient with JAK2 associated post-polycythemia myelofibrosis ; volume:10 ; number:1 ; day:30 ; month:6 ; year:2015 ; pages:1-6 ; date:12.2015
Orphanet journal of rare diseases ; 10, Heft 1 (30.6.2015), 1-6, 12.2015
- Creator
-
Shinar, Yael
Tohami, Tali
Livneh, Avi
Schiby, Ginette
Hirshberg, Abraham
Nagar, Meital
Goldstein, Itamar
Cohen, Rinat
Kukuy, Olga
Shubman, Ora
Sharabi, Yehonatan
Gonzalez-Roca, Eva
Arostegui, Juan I.
Rechavi, Gideon
Amariglio, Ninnette
Salomon, Ophira
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-015-0298-6
- URN
-
urn:nbn:de:101:1-2021082121174392391612
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shinar, Yael
- Tohami, Tali
- Livneh, Avi
- Schiby, Ginette
- Hirshberg, Abraham
- Nagar, Meital
- Goldstein, Itamar
- Cohen, Rinat
- Kukuy, Olga
- Shubman, Ora
- Sharabi, Yehonatan
- Gonzalez-Roca, Eva
- Arostegui, Juan I.
- Rechavi, Gideon
- Amariglio, Ninnette
- Salomon, Ophira
- SpringerLink (Online service)
Other Objects (12)
Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis
JAK2 Negative Polycythemia Vera
Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis
Cerebral venous sinus thrombosis associated with JAK2 V617F mutation-related pre-primary myelofibrosis: a case report and literature review
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
The Prevalence of JAK2 Exon 12 Mutations in Vietnamese Patients with JAK2 V617F-Negative Polycythemia Vera: Frequent or Rare?
Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
Concomitant and atypical JAK2 and MPL mutations in patients with JAK2V617F and MPLW515L positive myelofibrosis
Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis
JAK2 Negative Polycythemia Vera
Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis
Cerebral venous sinus thrombosis associated with JAK2 V617F mutation-related pre-primary myelofibrosis: a case report and literature review
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
The Prevalence of JAK2 Exon 12 Mutations in Vietnamese Patients with JAK2 V617F-Negative Polycythemia Vera: Frequent or Rare?
Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
Concomitant and atypical JAK2 and MPL mutations in patients with JAK2V617F and MPLW515L positive myelofibrosis
Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis
JAK2 Negative Polycythemia Vera
Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis
Cerebral venous sinus thrombosis associated with JAK2 V617F mutation-related pre-primary myelofibrosis: a case report and literature review
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
The Prevalence of JAK2 Exon 12 Mutations in Vietnamese Patients with JAK2 V617F-Negative Polycythemia Vera: Frequent or Rare?
Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia